

**Supplementary Table 1. The detailed reimbursement guidelines for nucleos(t)ide analogs therapy by the National Health Insurance Service in Taiwan.**

Clinical status	Reimbursement criteria for nucleos(t)ide analogs therapy in CHB patients
Decompensated	PT $\geq$ 3sec or Total bilirubin $\geq$ 2mg/dL
Cirrhosis or HCC	Serum HBV DNA $\geq$ 2,000 IU/mL
HBeAg-positive	Serum ALT $\geq$ 200 U/mL or ALT $\geq$ 80 but <200 U/Ml and serum HBV DNA $\geq$ 20,000 IU/mL
HBeAg-negative	Serum HBV DNA $\geq$ 2,000 IU/mL and serum ALT $\geq$ 80 U/Ml more than twice a half year (with an interval of 3 months each time)

Abbreviation: HBeAg: hepatitis B e antigen. CHB: chronic hepatitis B. HBV: hepatitis B virus. AST: aspartate aminotransferase. ALT: alanine aminotransferase. HCC: hepatocellular carcinoma.

**Supplementary Table 2. 3-year, 5-year, and 10-year cumulative incidence of hepatocellular carcinoma (life table method).**

	MVR (N=1285)	LLV (N=1351)	HBV DNA>2000 (N=3027)	
HCC incidence	%	%	%	p-value <sup>a</sup>
3y	3.64	3.56	4.38	0.349
5y	4.98	4.96	6.68	0.044 <sup>b</sup>
10y	10.54	9.51	12.37	0.034 <sup>c</sup>

Abbreviation: LLV: low-level viremia. MVR: maintained virological response. HBV: hepatitis B virus. HCC: hepatocellular carcinoma.

<sup>a</sup> Log-rank test.

<sup>b</sup> Post-hoc test with Scheffe's method: HBV-DNA >2000 vs. MVR (p-value: 0.075); LLV vs. MVR (p-value: 0.999); HBV-DNA >2000 vs. LLV (p-value: 0.076)

<sup>c</sup> Post-hoc test with Scheffe's method: HBV-DNA >2000 vs. MVR (p-value: 0.078); LLV vs. MVR (p-value: 0.970); HBV-DNA >2000 vs. LLV (p-value: 0.049)

**Supplementary Table 3. Score comparison table for predicting the risk of hepatocellular carcinoma in patients with low level viremia.**

---

Total Points 3 year HCC-free probability	
42	0.99
117	0.90
141	0.80
156	0.70
168	0.60

---

---

Total Points 5 year HCC-free probability	
31	0.99
106	0.90
130	0.80
145	0.70
157	0.60
166	0.50

---

---

Total Points 10 year HCC-free probability	
81	0.9
105	0.80
120	0.70
131	0.60
141	0.50
150	0.40
159	0.30
168	0.20

---

Abbreviation: HCC: hepatocellular carcinoma.